Atacand vs. Cozaar
This article was originally published in Pharmaceutical Approvals Monthly
Labeling for AstraZeneca's angiotensin II receptor blocker Atacand (candesartan) may report data showing superior reduction in diastolic blood pressure over Merck's ARB Cozaar (losartan), FDA's Cardiovascular & Renal Drugs Advisory Committee concludes July 18. AstraZeneca's two CLAIM studies showed 1.5 and 2.2 mm Hg greater reductions in DBP for once-daily Atacand vs. once-daily Cozaa
You may also be interested in...
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.